Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
|Videos|June 22, 2017
Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers
Author(s)Stephen M. Ansell, MD, PhD
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer
2
LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCL
4
Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer
5